×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Using Artificial Intelligence to Inform Regulatory and Development Strategies
Session Chair(s)
Nicholas Drago, MS, RAC
Associate Director, Global Regulatory Strategy
Bayer, United States
Artificial intelligence and data science can help increase the efficiency of drug development. We will explore how pharma companies and researchers are leveraging artificial intelligence to identify insights and make predictions about regulatory strategies and drug development, and what is needed for further adoption.
Learning Objective : Describe how artificial intelligence is being applied in the pharmaceutical industry to inform decisions about regulatory strategies and drug development; Discuss what is needed to enable further use of artificial intelligence to support decision making.
Speaker(s)
Can Artificial Intelligence Inform Regulatory Strategy?
Andrew Robertson, LLM, PMP
Takeda, United States
Vice President, Head of Global Regulatory Policy and Innovation
Estimating and Predicting the Probabilities of Success of Clinical Trials: A Data Science Perspective
Andrew Lo, PhD, MA, MBA, PMP
Massachusetts Institute of Technology (MIT), United States
Charles E. and Susan T. Harris Professor of Finance, Sloan School of Management
Have an account?